Kling BioTherapeutics is a newly-formed Amsterdam UMC spin-off that is discovering and developing innovative antibody and antibody-derived drugs to treat cancer and infectious disease patients. With its lead program preparing to enter human clinical trials, Kling is well positioned to become an immuno-oncology biotech leader with a novel discovery platform and a robust pipeline of first in class oncology antibodies. Amsterdam UMC has partnered with U.S.-based venture capital firm Time BioVentures to build Kling, and is excited by the company’s rapid progress in attracting a world-class management team of seasoned drug development executives with impressive track records bringing breakthrough products to patients. The company’s offices and labs are located on Amsterdam UMC’s Meibergdreef campus.
Anya Biotech, representing Amsterdam UMC, has won the second edition of the Proefdiervrij Venture Challenge on the 22nd of April 2022. Their winning innovation is based on research from the Department of Medical Biology at the AMC. The team takes home €25.000, – in prize money to kick-start their venture based on human heart models […]
NewsEvery language contains riddles and secrets, currently there are seven thousand+ known languages. A treasure trove of colourful, curious and enigmatic stories. Every language tells a story about and gives a picture of the culture and the people that speak or have spoken this language. And every language is full of riddles and secrets that […]
NewsSem Vijverberg – PhD Candidate at Vrije Universiteit Amsterdam – and University of Amsterdam PostDoc researcher Tijmen Bakker have been selected as participants in the Faculty of Impact, and will be taking part in an intensive two year program where ten ambitious scientists work with each other and with a selection of experts to conquer […]
News